inner-banner-3

Products

Hyalgan®

Hyalgan® contains hyaluronic acid, which is a natural polymer of glycosaminoglycan found in joint cartilage and synovial fluid. The hyaluronic acid in Hyalgan® is processed by a patented molecular filtration procedure. The efficacy and safety of Hyalgan® for different osteoarthritis (OA) joints, such as knee, ankle, shoulder, etc., have been well-proven in numerous clinical studies1.

 

In OA patients, the molecular weight and concentration of the hyaluronic acid in the synovial fluid are lower compared to healthy joint, reducing its protective effect2. Hyalgan® injection replenishes and boosts the normal production of synovial fluid in joints to relieve pain and other symptoms1.

Features
  • First hyaluronic acid therapy for OA knee pain approved in the US by FDA in 19973
  • 50 million injections given worldwide since launch1
  • Has been studied in 110 clinical trials1
Composition

Hyaluronic acid sodium salt 20 mg.

Indication

For the treatment of pain in osteoarthritis of the knee.

Dosage

2 mL of Hyalgan® (20 mg) administered intra-articularly once a week for 5 weeks or as directed by the physician.

Pack Size

One 2 mL pre-filled syringe.

Precaution
  • Products administration should be performed exclusively by licensed physicians.
  • For details, please refer to package insert.
Storage
  • Do not store above 25 °C.
  • Keep out of reach of children.
Disclaimer & Reference

The content on this site is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician with any questions you may have regarding a medical condition.

 

Reference

  1. Fidia Farmaceutici S.p.A.,. Hyalgan (sodium hyaluronate). Data on file. Accessed February 2, 2026. https://www.hyalgan.com/wp-content/uploads/2016/05/HyalganPatInfoPDFupdate513.pdf#page=2.88
  2. Altman R, Manjoo A, Fierlinger A, Niazi F, Nicholls M. The mechanism of action for hyaluronic acid treatment in the osteoarthritic knee: a systematic review. BMC Musculoskelet Disord. 2015;16:321. doi:10.1186/s12891-015-0775-z
  3. U.S. Food and Drug Administration. Hyalgan - accessdata.fda.gov. Accessed February 2, 2026. https://www.accessdata.fda.gov/cdrh_docs/pdf/P950027a.pdf